Sources

9 Total Sources

GLP-1 Drugs Cut Stage IV Progression in 4 Cancers, With 10.0% vs 22.3% in Lung Cases

The ASCO Post3d ago

GLP-1 Agonists Linked to Reduced Metastatic Progression in Obesity-Related Cancers

GLP-1 drugs show potential far beyond diabetes and obesity

oaepublish.com19h ago

Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists -

Instagram3d ago

Can GLP-1 receptor agonists reduce the risk of obesity-related cancers? At #ASCO2025, NYU Grossman School of Medicine student Lucas Mavromatis presented findings from a large database analysis comparing patients with diabetes and

GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care | OncLive

U.S. News & World Report3d ago

Can GLP-1s Treat Cancer? Ozempic and Cancer Risk Explained | U.S. News

Emerging research reveals GLP-1 drugs like Ozempic may combat diseases beyond obesity, including cancer and addiction, though caution is advised with unverified claims.

Physician's Weekly3d ago

Beyond A1c Is Not Enough: How GLP-1 Therapy Is Changing Frontline Care | www.PhysiciansWeekly.com

jheor.org3d ago

Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios | Published in Journal of Health Economics and Outcomes Research